Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Friday 28 September, 2018

AstraZeneca PLC

Previous Announcement Regarding Appointment Of NED

RNS Number : 3957C
AstraZeneca PLC
28 September 2018
 

28 September 2018 16:00 BST

 

PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NON-EXECUTIVE DIRECTOR

 

AstraZeneca PLC (the Company) today announced that with the Company's agreement, Joseph G. Peter (Joe Peter) has withdrawn his candidacy as a Non-Executive Director and a member of the Audit Committee.  His proposed appointment to these positions was announced by the Company on 6 September 2018 and was to have become effective on 1 October 2018.  Mr Peter's decision is for reasons that are not related to the Company.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations



Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677




  Investor Relations



 

Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

Cardiovascular; Metabolism

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Josie Afolabi

Other

+44 203 749 5631

Craig Marks

Finance; Fixed Income

+44 7881 615 764

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

US toll-free


+1 866 381 7277

 

Adrian Kemp
Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAZVLFLVKFLBBZ

a d v e r t i s e m e n t